

Kunie ROUSSEL-ANDO

Laboratory of Histology, Neuroanatomy and Neuropathology,
Faculty of Medicine, Free university of Brussels (ULB)



BSc in Biological Sciences, University of Tsukuba, Ibaraki, Japan, 2002.
MSc in Neuroscience at University of Edinburgh, Scotland, UK, 2003.
PhD in Neuroscience at University of Lille 2, France, 2007.

IAP postdoctoral fellow at the Free university of Brussels, Belgium 2007-2011.
Associated assistant in ICM institute, UPMC, Paris France 2011-2014
FNRS postdoctoral fellow at postdoctoral fellow at the Free university of Brussels,
Belgium 2014-2017.

E-mail: Kunie.Ando@ulb.ac.be
Phone: + 32 -(0)2-555-6333

Keywords

Alzheimer's disease, Tau, phosphorylation, transgenic mice, and neurofibrillary tangles.

Science

Alzheimer disease is characterized by two neuropathological lesions: so-called tau pathology and amyloid pathology. The level of tau pathology highly correlates with the progression of dementia in Alzheimer patients than amyloid load, while the disease causing mechanisms are still unknown. My research activities aim to better understand the tau pathology progression by studying post-mortem human Alzheimer brains, transgenic mice or cell culture. My long-term goal is eventually to develop therapeutic methods to prevent/reduce tau pathology.

Publications

1. Frederick C*, **Ando K***, Leroy K, Héraud C, Suain V, Buée L, Brion JP. Rapamycin ester analog CCI-779/Temsirolimus alleviates tau pathology and improves motor deficit in mutant tau transgenic mice. Accepted to **J Alzheimers Dis.** (SCI Impact factor 2012 : 4.174)
2. **Ando K***, Laborde Q*, Lazar A, Godefroy D, Youssef I, Amar M, Pooler AM, Potier MC, Delatour B, Duyckaerts C. Inside Alzheimer brain with CLARITY: senile plaques, neurofibrillary tangles and axons in 3-D. Accepted to **Acta Neuropathologica.** (SCI Impact factor 2013 : 9.777)
3. **Ando K***, Kabova A*, Stygelbout V, Leroy K, Héraud C, Frédérick C, Suain V, Yilmaz Z, Authelet M, Dedecker R, Potier MC, Duyckaerts C, Brion JP. (*: authors equally contributed). Vaccination with Sarkosyl insoluble PHF-tau decrease NFTs formation in aged tau transgenic mouse model: a pilot study. *Journal of Alzheimer Disease.* **J Alzheimers Dis.** 2014;40:S135-S145. (SCI Impact factor 2012 : 4.174)
4. Stygelbout V, Leroy K, Pouillon V, **Ando K**, D'Amico E, Jia Y, Luo HR, Duyckaerts C, Erneux C, Schurmans S, Brion JP. Inositol trisphosphate 3-kinase

- B is increased in human Alzheimer brain and exacerbates mouse Alzheimer pathology. Accepted to **Brain**. 2013. (SCI Impact factor 2013 : 10.226)
5. Héraud C, Goufak D, **Ando K**, Leroy K, Suain V, Yilmaz Z, De Decker R, Authelet M, Laporte V, Octave JN, Brion JP. Increased misfolding and truncation of tau in APP/PS1/tau transgenic mice compared to mutant tau mice. **Neurobiol Dis**. 2013 Sep 27;62C:100-112. (SCI Impact factor 2012 : 5.624)
 6. **Ando K**, Brion JP, Stygelbout V, Suain V, Authelet M, Dedecker R, Chanut A, Lacor P, Lavaur J, Sazdovitch V, Rogaeva E, Potier MC, Duyckaerts C. Clathrin adaptor CALM/PICALM is associated with neurofibrillary tangles and is cleaved in Alzheimer's brains. **Acta Neuropathol**. 2013 Jun;125(6):861-78. (SCI Impact factor 2013 : 9.777)
 7. Vardarajan B, Vergote D, Tissir F, Logue M, Yang J, Daude N, **Ando K**, Rogaeva E, Lee J, Cheng R, Brion JP, Ghani M, Shi B, Baldwin CT, Kar S, Mayeux R, Fraser P, Goffinet AM, George-Hyslop PS, Farrer LA, Westaway D. Role of p73 in Alzheimer disease: lack of association in mouse models or in human cohorts. **Mol Neurodegener**. 2013 Feb 15;8:10. (SCI Impact factor 2012 : 4.01)
 8. Poncelet L, Héraud C, Springinsfeld M, **Ando K**, Kabova A, Beineke A, Peeters D, Op De Beeck A, Brion JP. Identification of feline panleukopenia virus proteins expressed in Purkinje cell nuclei of cats with cerebellar hypoplasia. **Vet J**. 2013 Jun;196(3):381-7. (SCI Impact factor 2012 : 2.424)
 9. Poncelet L, Springinsfeld M, **Ando K**, Héraud C, Kabova A, Brion JP. Expression of transferrin receptor 1, proliferating cell nuclear antigen, p27(Kip1) and calbindin in the fetal and neonatal feline cerebellar cortex. **Vet J**. 2013 Jun;196(3):388-93. (SCI Impact factor 2012 : 2.424)
 10. **Ando K**, Dourlen P, Sambo AV, Bretteville A, Bélarbi K, Vingtheux V, Eddarkaoui S, Drobecq H, Ghestem A, Bégard S, Demey-Thoma E, Melny P, Smet C, Lippens G, Maurage CA, Caillet-Boudi ML, Verdier Y, Vinh J, Landrieud I, Galas MC, Blum D, Hamdane M, Sergeant N, Buée L. Pin1 phosphorylation is modulated by Tau proteins during neurofibrillary degeneration. Accepted to **Neurobiol. of aging**. 2013 Mar;34(3):757-69. (SCI Impact factor 2012 : 6.166)
 11. Leroy K*, **Ando K***, Laporte V, De Decker R, Suain V, Authelet M, Héraud C, Pierrot N, Yilmaz Z, Octave JN, Brion JP. (*: authors equally contributed) Tau depletion rescues cellular and behavioral deficits in Alzheimer transgenic mice expressing mutant APP and PS1. **Am J Pathol**. 2012 Dec;181(6):1928-40. (5-year Impact factor : 5.327)
 12. Gilley J, Seereeram A, **Ando K**, Brion JP, Mosely S, Kerschensteiner M, Misgeld T, Anderton BH, Hanger D, and Coleman M. Altered mitochondrial transport and reduced tau phosphorylation in a healthy FTDP-17T tau knock-in mouse. **Neurobiol Aging**. 2012 Mar;33(3):621.e1-621.e15. (SCI Impact factor 2012 : 6.166)
 13. **Ando K**, Leroy K, Heraud C, Yilmaz Z, Authelet M, Suain V, De Decker R, Brion

- JP. Accelerated human mutant tau aggregation by knocking out murine tau in a transgenic mouse model. **Am J Pathol.** 2011 Feb;178(2):803-16. (5-year Impact factor : 5.327)
14. **Ando K**, Leroy K, Heraud C, Kabova A, Yilmaz Z, Authelet M, Suain V, De Decker R, Brion JP. Deletion of murine tau gene increases tau aggregation in a human mutant tau transgenic mouse model. **Biochem Soc Trans.** 2010 Aug;38(4):1001-5. (5-year Impact factor : 3.267)
 15. Brion JP, **Ando K**, Heraud C, Leroy K. Modulation of tau pathology in tau transgenic models. **Biochem Soc Trans.** 2010 Aug;38(4):996-1000. (5-year Impact factor : 3.267)
 16. Leroy K*, **Ando K***, Héraud C, Yilmaz Z, Authelet M, Boeynaems JM, Buée L, De Decker R, Brion JP. (*: authors equally contributed) Lithium treatment arrests the development of neurofibrillary tangles in mutant tau transgenic mice with advanced neurofibrillary pathology. **J Alzheimers Dis.** 2010;19(2):705-19. (SCI Impact factor 2012 : 4.174)
 17. Bretteville A, **Ando K**, Ghestem A, Loyens A, Bégard S, Beauvillain JC, Sergeant N, Hamdane M, Buée L. Two-dimensional electrophoresis of tau mutants reveals specific phosphorylation pattern likely linked to early tau conformational changes. **PLoS One.** 2009;4(3):e4843. (SCI Impact factor 2012 : 3.730)
 18. Schindowski K, Belarbi K, Bretteville A, **Ando K**, Buée L. Neurogenesis and cell cycle-reactivated neuronal death during pathogenic tau aggregation. **Genes Brain Behav.** 2008 Feb;7 Suppl 1:92-100. (SCI Impact factor 2012 : 3.597)
 19. Dourlen P, **Ando K**, Hamdane M, Bégard S, Buée L, Galas MC. The peptidyl prolyl cis/trans isomerase Pin1 downregulates the Inhibitor of Apoptosis Protein Survivin. **Biochim Biophys Acta.** 2007 Sep;1773(9):1428-37. (5-year Impact factor : 4.947)
 20. Hamdane M, Dourlen P, Bretteville A, Sambo AV, Ferreira S, **Ando K**, Kerdraon O, Bégard S, Geay L, Lippens G, Sergeant N, Delacourte A, Maurage CA, Galas MC, Buée L. Pin1 allows for differential Tau dephosphorylation in neuronal cells. **Mol Cell Neurosci.** 2006 May-Jun;32(1-2):155-60. (5-year Impact factor : 3.769)
 21. Galas MC, Dourlen P, Bégard S, **Ando K**, Blum D, Hamdane M, Buée L. The peptidylprolyl cis/trans-isomerase Pin1 modulates stress-induced dephosphorylation of Tau in neurons. Implication in a pathological mechanism related to Alzheimer disease. **J Biol Chem.** 2006 Jul 14;281(28):19296-304. (SCI Impact factor 2012: 4.651)
 22. Bunai F, **Ando K**, Ueno H, Numata O. Tetrahymena eukaryotic translation elongation factor 1A (eEF1A) bundles filamentous actin through dimer formation. **J Biochem.** 2006 Sep;140(3):393-9. (SCI Impact factor 2012 : 2.719)